Pharmaceutical Executive January 19, 2026
Key Takeaways
- Pharmaceutical companies have raised list prices for 872 brand-name medications, with a median increase of 4% in 2026.
- The Great Healthcare Plan aims to lower drug prices and insurance premiums, building on Most-Favored-Nation deals.
- Companies in the TrumpRx platform, like Pfizer and AstraZeneca, continue to raise drug prices despite efforts to provide affordable medications.
- Experts debate the significance of list prices, suggesting they may not heavily impact most Americans’ prescription costs.
Despite pledges to lower drug costs through Trump-backed pricing deals and direct-to-patient programs, pharmaceutical companies entered 2026 by raising list prices on hundreds of brand-name medicines, underscoring the limited impact of recent policy efforts on the broader U.S. drug pricing landscape.
After a year filled...
Today's Sponsors
Today's Sponsor